I serve as vice chair for clinical affairs at the OSUCCC – James, surgeon-in-chief for the OSUCCC – James, as well as surgeon-in-chief for The Ohio State University Health Care System, and professor and director of Ohio State’s division of surgical oncology. I’m also the director of the Sarcoma Research Laboratory at Ohio State.
Research has been an important part of my career. I have been entrusted to run many research efforts, including a recent $15 million Specialized Program of Research Excellence (SPORE) grant with the National Cancer Institute (NCI) that targets some of the most difficult-to-treat forms of sarcoma. We are driven every day knowing that time is of the essence for cancer patients and their families.
To stay involved with the latest cutting-edge therapies, I serve as chair of the American Joint Committee on Cancer’s Sarcoma Committee, and as a member of the advisory boards of the Sarcoma Foundation of America, the UICC TNM Expert Advisory Panel on Sarcoma, and the Bone and Soft Tissue Cancer Protocol Review Panel of the College of American Pathologists.
- Rated in the top 10 percent of physicians in the nation for patient satisfaction, 2016
Saint Louis University School of Medicine
Rush Presbyterian Hospital
1/1/1980 - 6/30/1982
University of Chicago Hospitals
7/1/1978 - 12/30/1979
Specialties and conditions I treat
- Surgical Oncology
- Gastrointestinal Stromal Tumors
- Connective and Soft Tissue Cancers
- Muscle Tissue Cancers
- Sarcoma, Kaposi
- Spine Sarcoma
Locations where I practice
More about my work
MD Anderson Cancer Center
7/1/1982 - 6/30/1984
American Board of Surgery
News about me
Consulting and Related Relationships
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 03/28/17, Dr. Pollock has reported no financial relationships with medical device, research and/or drug companies.